Therapeutic drug monitoring in the treatment of tuberculosis patients

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 83-86

  Magis Escurra, Cecile ^a   van den Boogaard, Jossy ^a   IJdema, Dirk ^a   Boeree, Martin ^a   Aarnoutse, Rob ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Therapeutic drug monitoring; Tuberculosis

Indexed keywords

ETHAMBUTOL; FLUORODEOXYGLUCOSE F 18; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY MASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG MONITORING; GENOTYPE; HUMAN; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; THERAPY DELAY; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ALCOHOLISM; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; ETHAMBUTOL; HUMANS; INDIVIDUALIZED MEDICINE; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; SCHIZOPHRENIA; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84856800812     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.12.001     Document Type: Article

References (28)

1. World Health Organization WHO report 2011. Global Tuberculosis Control 2011, WHO/HTM/TB/2011.16, WHO, Geneva, Switzerland, Available from:. http://www.who.int.
2. Ray J., Gardiner I., Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003, 33:229-234.
3. Kimerling M.E., Phillips P., Patterson P., Hall M., Robinson C.A., Dunlap N.E. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998, 113:1178-1183.
4. Mehta J.B., Shantaveerapa H., Byrd R.P., Morton S.E., Fountain F., Roy T.M. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001, 120:1520-1524.
5. Um S.W., Lee S.W., Kwon S.Y., Yoon H.I., Park K.U., Song J., et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007, 11:972-978.
6. Narita M., Hisada M., Thimmappa B., Stambaugh J., Ibrahim E., Hollender E., et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001, 32:515-517.
7. Holland D.P., Hamilton C.D., Weintrob A.C., Engemann J.J., Fortenberry E.R., Peloquin C.A., et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009, 29:503-510.
8. Peloquin C.A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169-2183.
9. Holdiness M.R. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinetics 1984, 9:511-544.
10. Peloquin C.A., Jaresko G.S., Yong C.L., Keung A.C., Bulpitt A.E. Population pharmacokinetic modeling of isoniazid, rifampicin and pyrazinamide. Antimicrob Agents Chemother 1997, 12:2670-2679.
11. Nijland H.M., Ruslami R., Stalenhoef J.E., Nelwan E.J., Alisjahbana B., Nelwan R.H., et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43:848-854.
12. McIlleron H., Wash P., Burger A., Norman J., Folb P.I., Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006, 50:1170-1177.
13. Aarnoutse R.E., Schapiro J.M., Boucher C.A., Hekster Y.A., Burger D.M. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?. Drugs 2003, 63:741-753.
14. Yew W.W. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit 1998, 20:469-472.
15. Heysell S.K., Moore J.L., Keller S.J., Houpt E.R. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010, 16:1546-1553.
16. Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT). Richtlijn medicamenteuze behandeling van tuberculose 2005.Available from: (last accessed 17 January 2011). http://www.nvalt.nl/uploads/753/7240/4933_nvalt-richtlijntuberculosebinnenwerkdef_pp_10.pdf.
17. Diacon A.H., Patientia R.F., Venter A., Van Helden P.D., Smith P.J., McIlleron H., et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007, 51:2994-2996.
18. Polasa K., Murthy K.J., Krishnaswamy K. Rifampicin kinetics in undernutrition. Br J Clin Pharmacol 1984, 17:481-484.
19. Jayaram R., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., Jayashree R., et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003, 47:2118-2124.
20. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007, 51:3781-3788.
21. Gumbo T., Louie A., Liu W., Brown D., Ambrose P.G., Bhavnani S.M., et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007, 51:2329-2336.
22. Jayaram R., Shandil R.K., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004, 48:2951-2957.
23. Gumbo T., Dona C.S., Meek C., Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel invitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009, 53:3197-3204.
24. Srivastava S., Musuka S., Sherman C., Meek C., Leff R., Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. JInfect Dis 2010, 201:1225-1231.
25. Weiner M., Burman W., Vernon A., Benator D., Peloquin C.A., Khan A., et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003, 167:1341-1347.
26. Weiner M., Benator D., Burman W., Peloquin C.A., Khan A., Vernon A., et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005, 40:1481-1491.
27. Chang K.C., Leung C.C., Yew W.W., Kam K.M., Yip C.W., Ma C.H., et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis 2008, 27:467-472.
28. Horne D.J., Royce S.E., Gooze L., Narita M., Hopewell P.C., Nahid P., et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010, 10:387-394.